Maze Therapeutics price target raised to $34 from $19 at Guggenheim

Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on Maze Therapeutics (MAZE) to $34 from $19 and keeps a Buy rating on the shares after the company announced clinical results from the Phase 1 healthy volunteer study of MZE782. The healthy volunteer urinary Phe data exceeded a 10-times threshold with the reported 24-55-times increase, indicating a potentially superior profile relative to comps, and the MZ782 data imply the medicine has the potential to beat on efficacy, the analyst tells investors.